Table 1 Mendelian randomization analysis on metabolites, lipids and proteins against incident type 2 diabetes

From: Identification of biomarkers for glycaemic deterioration in type 2 diabetes

Metabolites

variable

method

nsnp

Beta

Lower

Upper

P-value

Egger intercept

Q

Q(df)

Q(P-value)

AADA

IVW

2

0.02

-0.09

0.13

0.77

 

0.02

1

0.88

Citrulline

IVW

6

-0.01

-0.29

0.28

0.97

-0.04

83.02

5

1.95·10-16

Isoleucine

IVW

5

-0.06

-0.94

0.83

0.90

-0.11

127.69

4

1.22·10-26

Leucine

IVW

6

-0.08

-0.74

0.58

0.81

-0.07

127.77

5

7.09·10-26

Lipids

variable

method

nsnp

Beta

Lower

Upper

P-value

Egger intercept

Q

Q(df)

Q(P-value)

PE 18:0;0_18:2;0

IVW

3

-0.07

-0.12

-0.02

3.89·10-3

0.02

5.53

2

0.06

SM 42:2;2

IVW

2

0.00

-0.07

0.07

0.99

 

0.91

1

0.34

TAG 50:1;0

IVW

2

0.01

-0.04

0.05

0.75

 

0.00

1

0.97

Proteins

variable

method

nsnp

Beta

Lower

Upper

P-value

Egger intercept

Q

Q(df)

Q(P-value)

GDF15

IVW

8

0.03

0.01

0.05

2.68·10-3

0.01

8.83

7

0.27

IL-18Ra

IVW

14

0.02

0.003

0.03

0.01

0.00

6.75

13

0.91

FAS

IVW

4

0.05

0.005

0.09

0.03

0.00

6.34

3

0.10

RTN4R

IVW

10

-0.01

-0.03

0.01

0.28

-0.01

4.16

9

0.90

ENPP7

IVW

4

0.01

-0.01

0.02

0.34

0.00

0.85

3

0.84

CRELD1

IVW

7

0.01

-0.01

0.02

0.43

0.01

7.33

6

0.29

  1. IVW inverse variance weighting, nsnp, number of instruments. Statistical test MR: Inverse variance weighted regression; statistical test heterogeneity: Cohran’s Q test.